003120.KS
Ilsung Is Co., Ltd.
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 20,650.00
+0.49%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 65.2B | 64.3B | 69.0B | 78.1B | 61.2B |
| Cost of Revenue | 37.8B | 37.2B | 42.0B | 43.3B | 33.3B |
| Gross Profit | 27.4B | 27.1B | 27.0B | 34.7B | 27.9B |
| Operating Expenses | |||||
| R&D Expense | 1.3B | 1.3B | 354.4M | 588.1M | 1.5B |
| SG&A Expense | 24.3B | 21.9B | 23.1B | 41.1B | 14.8B |
| General & Admin Expense | 1.4B | 1.8B | 2.3B | 2.6B | 1.6B |
| Selling & Marketing Expense | 20.1B | 20.1B | 20.8B | 20.2B | 13.2B |
| Other Expenses | 6.7B | 10.1B | 13.1B | 829.3M | 10.3B |
| Total Operating Expenses | 32.3B | 33.2B | 36.6B | 42.5B | 26.6B |
| Cost and Expenses | 70.1B | 70.5B | 78.5B | 85.8B | 60.0B |
| Operating Income (EBIT) | (4.9B) | (6.2B) | (9.5B) | (7.8B) | 1.3B |
| Non-Operating | |||||
| Interest Income | 5.3B | 5.6B | 7.6B | 8.5B | 92.1B |
| Interest Expense | 41.5M | 35.4M | 36.2M | 23.9M | 12.6M |
| Net Interest Income | 5.3B | 5.6B | 7.5B | 8.4B | 92.1B |
| Other Non-Op Income/Expense | 13.2B | 9.0B | 20.7B | (13.6B) | 141.0B |
| Non-Operating Income (excl Interest) | (7.5B) | — | (20.7B) | 13.6B | (141.0B) |
| EBT (Pre-Tax Income) | 8.3B | 2.8B | 11.2B | (21.3B) | 142.3B |
| Income Tax Expense | 2.7B | 1.7B | (1.9B) | (404.0M) | 33.6B |
| Bottom Line | |||||
| Net Income | 5.5B | 1.2B | 13.1B | (20.9B) | 108.7B |
| Earnings from Cont. Ops | 5.5B | 1.2B | 13.1B | (20.9B) | 108.7B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 5.5B | 1.2B | 13.1B | (20.9B) | 108.7B |
| Per Share | |||||
| Basic EPS | ₩571 | ₩170 | ₩1,921 | (₩2,994) | ₩2,906 |
| Diluted EPS | ₩571 | ₩170 | ₩1,921 | (₩2,994) | ₩2,906 |
| Revenue Per Share | ₩9,106 | ₩4,834 | ₩10,126 | ₩11,162 | ₩8,312 |
| Shares | |||||
| Basic Shares Outstanding | 7.2M | 13.3M | 6.8M | 7.0M | 7.4M |
| Diluted Shares Outstanding | 7.2M | 13.3M | 6.8M | 7.0M | 7.4M |
| Profitability Metrics | |||||
| EBITDA | (3.2B) | (2.8B) | 14.6B | (18.2B) | 145.3B |
| D&A | 3.2B | 3.3B | 3.4B | 3.1B | 3.0B |
| EBIT | (6.5B) | (6.2B) | 11.2B | (21.3B) | 142.3B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026